Allogeneic human skin replacement (Smith & ephew Biotherapeutics)

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameAllogeneic human skin replacement (Smith & ephew Biotherapeutics)
Drug Alias NameDFB Healthpoint allogeneic human skin replacementHuman skin replacement - Smith & Nephew BiotherapeuticsAlloxHP-802247
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Somatic cell > Fibroblast therapyCell and gene therapy > Cell therapy > Somatic cell > Keratinocytes therapy
Mechanisms of ActionTissue replacementsFibrinogen replacements
TargetsNot applicable
Therapy Area/IndicationsUlcerEpidermolysis Bullosa DystrophicaVaricose Ulcer +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[8] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSmith & Nephew
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAtlantic Health System IncHealthpoint Hospital
Active IndicationsN/A
Inactive IndicationsUlcerEpidermolysis Bullosa DystrophicaVaricose Ulcer +[4] 

Other Information

ATC CodeN/A
Related LinksN/A